Searched for
SUN PHARMA Q4 EARINGS
Zydus Lifesciences completes acquisition of AssertioThe company has successfully completed the cash tender offer, through wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding...- India adds 4.6 GWh of energy storage capacity in first quarter of 2026: ReportIndia saw a massive surge in battery energy storage capacity in early 2026. The country added 4.6 gigawatt-hours in the first three months,...
- India Inc's sales growth gathers pace in March quarter, led by autos and metals: RBI dataManufacturing companies saw sales jump 14.5 percent in the fourth quarter of 2025-26. Automobiles, electrical machinery, and non-ferrous me...
- Automobiles, electrical machinery push sales of listed private manufacturing companies in Q4: RBI dataIndian manufacturing companies saw sales jump 14.5 percent in early 2026. Automobiles, electrical machinery, and metals led this growth. Ov...
- Bonus bonanza! Last date to buy Brigade Enterprises shares for 1:3 bonus issue rewardBrigade Enterprises in May announced its first bonus issue in around seven years, along with the release of its Q4 results. It said its boa...
- BenQ bets big on B2B segment, but its biggest opportunity may still be in home entertainmentBenQ is integrating on-device generative AI into Indian classrooms with its new RP05 interactive display, simplifying teaching tasks. Beyon...
- Quote of the day by ‘A Farewell To Arms’ writer Ernest Hemingway: ‘When people talk listen completely. Don't be thinking what you're going to say..’ ; lessons on art of hearing from American literary iconErnest Hemingway, a Nobel Prize-winning author, emphasized the profound value of patient listening for learning and personal growth. He urg...
- PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...
- Olivia Rodrigo's new album is out now - but did you know she's 60% deaf in one ear?Olivia Rodrigo has shared a personal health detail. She lives with partial deafness in her left ear. This condition has been with her since...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
- Crude at $100, AI IPOs at $1 trillion, and gold on sale: What Peter McGuire says you should do nowPeter McGuire of Australia-Trading.com highlights a chaotic market driven by rumors and geopolitics, not fundamentals. He predicts crude oi...
- What is Planet Nine, and where is it? Mystery of large hidden planet beyond Neptune explainedWhat is Planet Nine, and where is it? The question has fascinated astronomers for years. Scientists believe a massive undiscovered planet m...
- The AI play no one is talking about: Why BofA is snapping up power & metals instead of ITBofA Securities India's Amish Shah advises shifting from IT to infrastructure, citing a 'dangerous gap' in consensus earnings forecasts. He...
- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun PharmaThe Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...
- Buy financials, healthcare, and manufactured exports; Pramod Gubbi on investing in a tricky marketIndia's Q4 earnings show recovery signs, with Nifty 100 profits up 13%. However, macro headwinds like rising crude oil prices and a depreci...
- Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividendSun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while re...
Load More
